Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.55 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.45 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.44 |
| ▸ | AXL | P30530 | 10/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 10/20 | 0.43 |
| ▸ | MERTK | Q12866 | 10/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240279 | 0.88 | AURKA (0.58) | AURKAAURKBAXLTYRO3MERTK | |
| SCHEMBL8247437 | 0.87 | AURKA (0.57) | AURKAAURKBMAPKAPK5PTK6AXL | |
| SCHEMBL8240330 | 0.81 | AURKA (0.63) | AURKAAURKBMAPKAPK5PTK6 | |
| SCHEMBL8241176 | 0.81 | AURKA (0.58) | AURKAAURKBMAPKAPK5PTK6AXL | |
| SCHEMBL14507230 | 0.81 | AURKA (0.58) | AURKAAURKBMAPKAPK5PTK6AXL | |
| SCHEMBL14530382 | 0.80 | AURKA (0.71) | AURKAAURKBMAPKAPK5PTK6 | |
| SCHEMBL8240162 | 0.80 | AURKA (0.62) | AURKAAURKBMAPKAPK5PTK6AXL | |
| SCHEMBL8246048 | 0.80 | AURKA (0.66) | AURKAAURKBMAPKAPK5PTK6JAK2 | |
| SCHEMBL8246792 | 0.80 | AURKA (0.62) | AURKAAURKBMAPKAPK5PTK6 | |
| SCHEMBL8240292 | 0.79 | AURKA (0.70) | AURKAAURKBMAPKAPK5PTK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | AURKA 91/4885AURKB 137/4885MAPKAPK5 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.